U.S. DOJ Seeks Medicaid Pricing Data From Ranbaxy
This article was originally published in PharmAsia News
Executive Summary
Ranbaxy Laboratories has come under the scrutiny of the U.S. Justice Department, which seeks documents and pricing data covering the drugs it supplies under the Medicaid program.